Global COPD clinical trial case
Global COPD clinical trial geography under realistic constraints
This illustrative COVARIS case tested whether a realistic five-country COPD clinical trial geography contained meaningful environmental stability differences before protocol lock. Using a combined temperature-humidity respiratory weather-stress measure, the analysis showed that overall environmental dispersion could be reduced by 15.3% in a constrained scenario that retained all countries and all zones. A winter-only robustness view showed a smaller but still positive reduction of 5.4%.
Why this case was built
Early COVARIS case work showed that environmental instability can be detected within countries and across clinical trial geographies. The next question was more relevant to real global clinical trial planning: can a broad global clinical trial geography contain meaningful room for improvement even when no single country or region alone explains the full result?
This case was built to test exactly that. The aim was not to show an unconstrained optimization exercise, but to examine whether several moderate changes in planned patient enrollment across countries and regions could make a global COPD clinical trial geography more stable before protocol lock.
Clinical trial setup
This illustrative case was constructed as a realistic global phase 3-style COPD clinical trial geography covering the United States, Germany, Spain, Brazil and South Korea. The geography was analysed as one integrated global setup rather than as a series of separate country cases.
All countries remained in scope in both baseline and constrained scenarios, and internal regions also remained in scope. The case therefore tested whether moderate shifts in planned patient enrollment across countries and regions could improve overall environmental stability without changing the country list or breaking the broader study structure.
Disease area: COPD
Countries: USA, Germany, Spain, Brazil, South Korea
Geography structure: Global multi-country phase 3-style setup
Scenario logic: All countries retained, all regions retained, moderate patient reweighting only
Disease-relevant environmental variable
The case used a combined Respiratory Weather Stress Index (RWSI) built from temperature and humidity. The rationale was that respiratory weather stress is not determined by temperature alone. Humidity shapes how thermally stressful ambient conditions become for the airways and therefore belongs in the same exposure logic rather than as an isolated parallel signal.
In this case, overall footprint dispersion was expressed as weighted SD on the Respiratory Weather Stress Index. On this page, that result is described more simply as overall environmental dispersion across the planned clinical trial geography.
Main result
Under a constrained scenario, overall environmental dispersion across the planned global COPD clinical trial geography was reduced by 15.3% versus baseline. The result was cumulative: all countries remained in scope, all internal regions remained in scope, and the improvement came from moderate changes in planned patient enrollment rather than from country removal or unconstrained redesign.
A winter-only robustness view showed a smaller but still positive reduction of 5.4% versus baseline. This suggests that the signal does not disappear under seasonal restriction, but that it is weaker than in the full-year model.
Country-level shifts
The cumulative result did not come from country removal or from one dominant switch in a single country. It came from several moderate changes in planned patient enrollment across the global clinical trial geography, including moderate subnational shifts between regions.
At country level, Brazil and Spain were moderately upweighted, Germany and South Korea were moderately downweighted, and the United States remained unchanged. This is what makes the case relevant to real global clinical trial planning: the signal emerged within a realistic five-country setup rather than through a theoretical redesign.
Why it matters
Global clinical trials are rarely planned in a fully flexible design space. Countries and regions, timelines, operational realities and commercial constraints shape what can actually be changed.
That is why this case matters. It shows that a planned global COPD clinical trial geography can contain meaningful environmental stability differences even when all countries remain in scope and only moderate changes in patient enrollment are allowed. The value does not necessarily lie in dramatic redesign in one place. It may lie in several plausible shifts across countries and regions that make the overall clinical trial geography more stable before protocol lock.
What this case shows — and what it does not show
This case shows that a realistic global COPD clinical trial geography can contain meaningful cumulative environmental stability differences before protocol lock. It shows that several moderate changes in planned patient enrollment across countries and regions can reduce overall environmental dispersion without removing countries or collapsing the broader study structure.
This case does not show treatment effect, exacerbation outcome, clinical causality or quantified economic gain. It does not argue that environmental variation should be removed from clinical trials as such. It shows something narrower and more practical: that environmental context can be measured, compared and made explicit early enough to support more disciplined clinical trial planning decisions.
Download sample report
See the format, structure and level of detail of an illustrative COVARIS sponsor-facing screening report based on this case.
Illustrative sponsor-facing example. Analytical logic and report structure reflect the current COVARIS approach.
COVARIS helps sponsors and CROs screen planned trial countries, regions and enrollment windows for disease-relevant environmental instability before protocol lock.
COVARIS does not predict outcomes or prove causal effects. It provides planning-stage environmental context intelligence for sponsor-led clinical trial decisions.
COVARIS ApS
2100 Copenhagen
Denmark
+45 25 30 30 28
CVR-no.: 46484673